Telavancin: The Long and Winding Road From Discovery to Food and Drug Administration Approvals and Future Directions

The Role of Telavancin in Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia

(2015) Christian E. Sandrock et al.   CLINICAL INFECTIOUS DISEASES

Telavancin: Mechanisms of Action, In Vitro Activity, and Mechanisms of Resistance

(2015) James A. Karlowsky et al.   CLINICAL INFECTIOUS DISEASES

The clinical positioning of telavancin in Europe

(2015) Robert Masterton et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Telavancin for refractory methicillin-resistantStaphylococcus aureusbacteremia and infective endocarditis

(2015) Michael A. Ruggero et al.   Infectious Diseases

Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival

(2014) G. Ralph Corey et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Revised Reference Broth Microdilution Method for Testing Telavancin: Effect on MIC Results and Correlation with Other Testing Methodologies

(2014) David J. Farrell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study

(2014) Martin E Stryjewski et al.   BMC INFECTIOUS DISEASES

Potential Role for Telavancin in Bacteremic Infections Due to Gram-Positive Pathogens: Focus on Staphylococcus aureus

(2014) G. R. Corey et al.   CLINICAL INFECTIOUS DISEASES

Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal disease

(2014) Steven L. Barriere et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection

(2014) Sharath S Hegde et al.   Expert Review of Anti-Infective Therapy

Quality Control MIC Ranges Used for Telavancin with Application of a Revised CLSI Reference Broth Microdilution Method

(2014) James E. Ross et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Comparative Activities of Telavancin Combined with Nafcillin, Imipenem, and Gentamicin against Staphylococcus aureus

(2013) Steven N. Leonard et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Methicillin-Resistant Staphylococcus aureus Therapy: Past, Present, and Future

(2013) K. A. Rodvold et al.   CLINICAL INFECTIOUS DISEASES

Telavancin versus vancomycin for bacteraemic hospital-acquired pneumonia

(2013) Martin E. Stryjewski et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers

(2013) Michael P. Ero et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Successful Treatment of Polymicrobial Calcaneal Osteomyelitis with Telavancin, Rifampin, and Meropenem

(2012) Mary Beth Brinkman et al.   ANNALS OF PHARMACOTHERAPY

Telavancin in Therapy of Experimental Aortic Valve Endocarditis in Rabbits Due to Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus

(2012) Yan Q. Xiong et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Telavancin Pharmacokinetics and Pharmacodynamics in Patients with Complicated Skin and Skin Structure Infections and Various Degrees of Renal Function

(2012) T. P. Lodise et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetics of Telavancin in Healthy Subjects and Patients with Infections

(2012) Emil Samara et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Acute renal insufficiency during telavancin therapy in clinical practice--authors' response

(2012) L. A. Marcos et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA)

(2011) Steven N. Leonard et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis

(2011) J. D. Twilla et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Successful treatment of methicillin-resistant Staphylococcus aureus mitral valve endocarditis with sequential linezolid and telavancin monotherapy following daptomycin failure

(2011) J. Joson et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Acute renal insufficiency during telavancin therapy in clinical practice

(2011) L. A. Marcos et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparative Efficacies of Human Simulated Exposures of Telavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus with a Range of Vancomycin MICs in a Murine Pneumonia Model

(2010) J. L. Crandon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Successful Treatment of Vancomycin-Intermediate Staphylococcus aureus Pacemaker Lead Infective Endocarditis with Telavancin

(2010) L. A. Marcos et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mass Balance and Pharmacokinetics of [14C]Telavancin following Intravenous Administration to Healthy Male Volunteers

(2010) J.-P. Shaw et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamics of Telavancin Studied in anIn VitroPharmacokinetic Model of Infection

(2010) Alasdair P. MacGowan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Registration Trials of Antibacterial Drugs for the Treatment of Nosocomial Pneumonia

(2010) Alfred Sorbello et al.   CLINICAL INFECTIOUS DISEASES

End Points in Hospital‐Acquired Pneumonia and/or Ventilator‐Associated Pneumonia Clinical Trials: Food and Drug Administration Perspective

(2010) Katherine A. Laessig   CLINICAL INFECTIOUS DISEASES

Recommended Design Features of Future Clinical Trials of Antibacterial Agents for Hospital‐Acquired Bacterial Pneumonia and Ventilator‐Associated Bacterial Pneumonia

(2010) Brad Spellberg et al.   CLINICAL INFECTIOUS DISEASES

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens

(2010) E. Rubinstein et al.   CLINICAL INFECTIOUS DISEASES

Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with telavancin

(2010) H. Nace et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Review of the Basic and Clinical Pharmacology of Sulfobutylether-β-Cydodextrin (SBECD)

(2010) David R. Luke et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Comparative Efficacies of Telavancin and Vancomycin in Preventing Device-Associated Colonization and Infection by Staphylococcus aureus in Rabbits

(2009) R. O. Darouiche et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Telavancin against Staphylococcus aureus Strains with Various Vancomycin Susceptibilities in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations

(2009) S. N. Leonard et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Telavancin Disrupts the Functional Integrity of the Bacterial Membrane through Targeted Interaction with the Cell Wall Precursor Lipid II

(2009) C. S. Lunde et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Telavancin Penetration into Human Epithelial Lining Fluid Determined by Population Pharmacokinetic Modeling and Monte Carlo Simulation

(2008) T. P. Lodise et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model

(2008) L.-Y. Yin et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects

(2008) S. L. Wong et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY